The Healthline report on the British Journal of Sports Medicine observational analysis of 147,374 participants across three cohorts (Health Professionals Follow-up, Nurses’ Health Studies) correctly flags the 13% all-cause mortality drop, 19% cardiovascular reduction, and 27% neurological benefit tied to 90–120 minutes of weekly strength training, with no added gains beyond that threshold. Yet this 30-year self-reported dataset remains purely observational, lacking randomization and relying on questionnaire data that omitted session duration, load intensity, and activities like Pilates—limitations that weaken causal claims. What the coverage underplays is the consistent pattern across related peer-reviewed work: a 2022 meta-analysis in Sports Medicine (n>1.2 million) showed resistance training independently lowers mortality even after adjusting for aerobic volume, while a 2019 JAMA Internal Medicine cohort (n=80,000+) revealed that combining strength work with moderate cardio amplifies benefits beyond either alone, a synergy the BJSM paper only touches. The original story also glosses over muscle-mass mechanisms—Hougen’s metabolic-health point is valid, but emerging data link higher lean mass to reduced inflammation and better insulin sensitivity, directly addressing sarcopenia-driven frailty in aging populations. Conflicts of interest appear minimal in the cited cohorts, yet self-selection bias among health professionals likely inflates adherence estimates. For viewers, the actionable takeaway stays simple: two hours weekly of body-weight or weighted moves is a low-barrier longevity lever, but future RCTs must test intensity thresholds to move from association to prescription.